NO20073146L - 4-cykloalkyl-substituerte tetrahydrokinolinderivater og deres anvendelse som medikamenter - Google Patents

4-cykloalkyl-substituerte tetrahydrokinolinderivater og deres anvendelse som medikamenter

Info

Publication number
NO20073146L
NO20073146L NO20073146A NO20073146A NO20073146L NO 20073146 L NO20073146 L NO 20073146L NO 20073146 A NO20073146 A NO 20073146A NO 20073146 A NO20073146 A NO 20073146A NO 20073146 L NO20073146 L NO 20073146L
Authority
NO
Norway
Prior art keywords
drugs
cycloalkyl
tetrahydroquinoline derivatives
substituted tetrahydroquinoline
prevention
Prior art date
Application number
NO20073146A
Other languages
English (en)
Norwegian (no)
Inventor
Hilmar Bischoff
Martina Wuttke
Heike Gielen-Haertwig
Volkhart Li
Carsten Schmeck
Michael Thutewohl
Alexandros Vakolopoulos
Olaf Weber
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20073146L publication Critical patent/NO20073146L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20073146A 2004-12-18 2007-06-19 4-cykloalkyl-substituerte tetrahydrokinolinderivater og deres anvendelse som medikamenter NO20073146L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
PCT/EP2005/013490 WO2006063828A1 (de) 2004-12-18 2005-12-15 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente

Publications (1)

Publication Number Publication Date
NO20073146L true NO20073146L (no) 2007-09-18

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073146A NO20073146L (no) 2004-12-18 2007-06-19 4-cykloalkyl-substituerte tetrahydrokinolinderivater og deres anvendelse som medikamenter

Country Status (27)

Country Link
US (2) US8124775B2 (enExample)
EP (1) EP1828137B1 (enExample)
JP (1) JP5132317B2 (enExample)
KR (1) KR20070090248A (enExample)
AR (1) AR055011A1 (enExample)
AT (1) ATE555097T1 (enExample)
AU (1) AU2005315770B2 (enExample)
BR (1) BRPI0519602A2 (enExample)
CA (1) CA2591397A1 (enExample)
CU (1) CU23452B7 (enExample)
CY (1) CY1112887T1 (enExample)
DK (1) DK1828137T3 (enExample)
DO (1) DOP2005000259A (enExample)
ES (1) ES2384980T3 (enExample)
GT (1) GT200500377A (enExample)
IL (1) IL184008A (enExample)
MA (1) MA29100B1 (enExample)
MX (1) MX2007007188A (enExample)
NO (1) NO20073146L (enExample)
PE (1) PE20060767A1 (enExample)
PL (1) PL1828137T3 (enExample)
PT (1) PT1828137E (enExample)
RU (1) RU2393151C2 (enExample)
SI (1) SI1828137T1 (enExample)
TW (1) TW200635900A (enExample)
UY (1) UY29276A1 (enExample)
WO (1) WO2006063828A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828136A1 (de) * 2004-12-18 2007-09-05 Bayer HealthCare AG (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
AU2009221179A1 (en) * 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
AU2011217206A1 (en) 2010-02-19 2012-08-02 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
MX2013000359A (es) * 2010-07-09 2013-02-11 Ube Industries Compuesto de piridina sustituida.
EP2675811A1 (en) 2011-02-17 2013-12-25 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
CA2860601C (en) 2012-01-06 2016-07-05 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
WO2025185022A1 (zh) * 2024-03-05 2025-09-12 维康平生(北京)生物科技有限公司 一种脂肪体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128681A1 (de) * 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19704244A1 (de) * 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) * 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) * 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
EP1828136A1 (de) * 2004-12-18 2007-09-05 Bayer HealthCare AG (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren

Also Published As

Publication number Publication date
UY29276A1 (es) 2006-07-31
CU23452B7 (es) 2009-12-01
US20080255068A1 (en) 2008-10-16
GT200500377A (es) 2006-11-09
IL184008A0 (en) 2007-10-31
ES2384980T3 (es) 2012-07-16
PL1828137T3 (pl) 2012-09-28
KR20070090248A (ko) 2007-09-05
TW200635900A (en) 2006-10-16
AR055011A1 (es) 2007-08-01
RU2393151C2 (ru) 2010-06-27
JP2008524145A (ja) 2008-07-10
AU2005315770A1 (en) 2006-06-22
PE20060767A1 (es) 2006-09-10
EP1828137B1 (de) 2012-04-25
WO2006063828A1 (de) 2006-06-22
DK1828137T3 (da) 2012-07-23
US8124775B2 (en) 2012-02-28
ATE555097T1 (de) 2012-05-15
DOP2005000259A (es) 2006-11-15
BRPI0519602A2 (pt) 2009-02-25
RU2007127127A (ru) 2009-01-27
MA29100B1 (fr) 2007-12-03
IL184008A (en) 2012-03-29
SI1828137T1 (sl) 2012-08-31
US20120142728A1 (en) 2012-06-07
MX2007007188A (es) 2007-08-14
EP1828137A1 (de) 2007-09-05
PT1828137E (pt) 2012-07-04
CA2591397A1 (en) 2006-06-22
AU2005315770B2 (en) 2011-12-08
JP5132317B2 (ja) 2013-01-30
CY1112887T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
CY1112887T1 (el) Παραγωγα 4-κυκλοαλκυλ-υποκατεστημενης τετραϋδροκινολινης και η χρηση τους ως φαρμακα
NO20072804L (no) Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer
BRPI0821644A2 (pt) Compostos derivados de benzimidazol carboxila ou hidroxila substituídos, processo para a sua preparação, composições farmacêuticas que os contêm, método para o tratamento terapêutico ou profilático de enfermidades que são moduladas por agonistas fxr e usos dos compostos
BRPI0507462A (pt) compostos de quinolina substituìdos
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2007111994A3 (en) Compounds and methods for treatment of disorders associated with er stress
NO20081425L (no) 8-substituerte benzoazepiner som Toll-lignende reseptormodulatorer
WO2007106236A3 (en) Pyrrolo-pyridine kinase modulators
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL159960A (en) Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
MX2007007187A (es) Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.
WO2006113910A3 (en) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
WO2004058174A3 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
MY177686A (en) Therapeutic agent for dyslipidemia
WO2007128086A3 (en) Novel viral replication inhibitor
EA200970398A1 (ru) Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр
BRPI0517961A (pt) piridinauréias de antranilamida como inibidores da cinase receptora do fator de crescimento endotelial vascular (vegf)
MX2015013625A (es) Nuevo derivado oxazolidina como inhibidor de la proteina de transferencia del ester de colesterilo (cetp), su metodo de preparacion, y composicion farmaceutica que lo comprende.
WO2007137098A3 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar
BRPI0911159A2 (pt) compostos derivados de ácido 4-dimetilaminobutírico, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico ou profilático de enfermidades que são moduladas por inibidres de cpt2 e uso destes compostos
BRPI0515725A (pt) piridinuréias de nicotinamida como inibidoras de cinase de receptor do fator de crescimento endotelial vascular (vegf)
UY28047A1 (es) Derivados de 7h-dibenzo(b,g)(1,5)dioxocin-5-ona y su uso
EP2636677A4 (en) CDK-HEMMENDES PYRROLOPYRIMIDINONCARBOXAMID DERIVATIVE OR PHARMACEUTICAL ACCEPTABLE SALT AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE PREVENTION OR TREATMENT OF LIVER CELL CARCINOMA

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application